^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
    Secondary therapy:
    FC
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet
    Title:

    Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Published date:
    10/02/2010
    Excerpt:
    408 patients were assigned to fludarabine, cyclophosphamide, and rituximab (chemoimmunotherapy group)...65% of patients in the chemoimmunotherapy group were free of progression compared with 45% in the chemotherapy group (hazard ratio 0·56 [95% CI 0·46-0·69], p<0·0001)...Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia.
    Secondary therapy:
    cyclophosphamide + fludarabine IV
    DOI:
    10.1016/S0140-6736(10)61381-5
    Trial ID:
    NCT00281918
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia

    Excerpt:
    ...- Confirmed diagnosis of CD20-positive CLL that meets the iwCLL criteria (Hallek et al, 2008)....
    Trial ID:
    NCT03847727
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

    Excerpt:
    ...- Participants with CD20-positive B-cell chronic lymphocytic leukemia eligible for first-line or second-line therapy according to the approved SPC...
    Trial ID:
    NCT01609023
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Jpn J Clin Oncol
    Title:

    A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia

    Published date:
    03/03/2021
    Excerpt:
    Although the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-naïve fit Japanese patients with CD20-positive CLL.
    Secondary therapy:
    cyclophosphamide + fludarabine oral
    DOI:
    10.1093/jjco/hyaa215
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Expert Rev Anticancer Ther
    Title:

    Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial

    Excerpt:
    In the German CLL Study Group (GCLLSG) CLL8 trial, treatment-naive, physically fit patients (aged 30-81 years) with CD20(+) CLL were randomly assigned...The CLL8 trial has demonstrated that an association of rituximab, fludarabine and cyclophosphamide is effective in prolonging progression-free survival and overall survival of patients with symptomatic CLL...
    Secondary therapy:
    cyclophosphamide + fludarabine IV
    DOI:
    10.1586/era.11.118